Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Molecular genetic and cytogenetic determinants of primary resistance or loss of the response to treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Aim of this study was to analyze molecular genetic and cytogenetic reasons for disease resistance to tyrosine kinase inhibitors (TKI) imatinib (IM) and nilotinib (NI) in patients with chronic myeloid leukemia (CML). Material and methods. A group of 32 CML patients with primary or acquired resistance...

Full description

Bibliographic Details
Main Authors: Kotlyarchuk K., Maslyak Z., Lukianova A., Tsyapka O., Selina I., Usenko A.
Format: Article
Language:English
Published: SE "Dnipropetrovsk medical academy of Health Ministry of Ukraine" 2015-09-01
Series:Medičnì Perspektivi
Subjects:
chronic myeloid leukemia
kinase domain mutations of BCR-ABL gene
chromosome aberrations
imatinib
nilotinib
Online Access:http://medpers.dsma.dp.ua/issues/2015/N3/67-73.pdf

Internet

http://medpers.dsma.dp.ua/issues/2015/N3/67-73.pdf

Similar Items